Epirium Bio Announces Positive Phase 1 Clinical Trial Results Evaluating MF-300 in Healthy Volunteers, A First-In-Class, Oral 15-PGDH Enzyme Inhibitor, For the Treatment of Sarcopenia

businesswire

Epirium Bio Announces Positive Phase 1 Clinical Trial Results Evaluating MF-300 in Healthy Volunteers, A First-In-Class, Oral 15-PGDH Enzyme Inhibitor, For the Treatment of Sarcopenia – NEWSnet – News… as it used to be

More Press Releases

May 10, 2026

ZSPC Investors Have Opportunity to Lead zSpace Inc. Securities Lawsuit Filed by The Rosen Law Firm

May 10, 2026

Bronstein, Gewirtz & Grossman LLC Urges Concorde International Group, Ltd. Investors to Act: Class Action Filed Alleging Investor Harm

May 10, 2026

Bronstein, Gewirtz & Grossman LLC Urges Stellantis N.V. Investors to Act: Class Action Filed Alleging Investor Harm

May 10, 2026

Epirium Bio Announces Positive Phase 1 Clinical Trial Results Evaluating MF-300 in Healthy Volunteers, A First-In-Class, Oral 15-PGDH Enzyme Inhibitor, For the Treatment of Sarcopenia

ZSPC Investors Have Opportunity to Lead zSpace Inc. Securities Lawsuit Filed by The Rosen Law Firm

Bronstein, Gewirtz & Grossman LLC Urges Concorde International Group, Ltd. Investors to Act: Class Action Filed Alleging Investor Harm

Bronstein, Gewirtz & Grossman LLC Urges Stellantis N.V. Investors to Act: Class Action Filed Alleging Investor Harm

Bronstein, Gewirtz & Grossman LLC Urges Power Solutions International, Inc. Investors to Act: Class Action Filed Alleging Investor Harm